Ⓐ
PeptiBrief
Evidence Library
open_label_extension · 2019

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

Simon JA, Kingsberg SA, Shumel B, et al. · Obstetrics & Gynecology
moderatePMID · 31599847Verified
View source
Plain-English summary

Provides longer follow-up than the pivotal trials but lacks a placebo control during extension.

Population
Premenopausal women completing prior HSDD trials
Intervention
Bremelanotide
Outcomes measured
Safety and sustained symptom response
Key findings
Reported sustained improvements with known adverse effects.
Limitations
Open-label extension; selected participants may differ from non-completers.
Risk of bias
Moderate due to open-label design and industry sponsorship.
Citation
Simon JA, Kingsberg SA, Shumel B, et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.